Guava Technologies says it provides new levels of flexibility and analysis with its RapidQuant IgG Assays for quantification of mouse and human antibodies
Used in combination with the Guava Express, ViaCount and other assays the new RapidQuant IgG assays provide unmatched antibody characterisation on a single cellular analysis platform - the EasyCyte Plus system.
With their simplicity and ease of use, the new microplate-based RapidQuant IgG Assays have raised the bar for IgG titering in tissue culture supernatants says Guava.
Designed to be time-saving, labour-saving and money-saving, RapidQuant assays eliminate the most tedious portions of antibody titering methods.
The no-wash RapidQuant assays are bead-based and rely on sensitive fluorescence detection for the quantitative measurements.
Standard curves are automatically produced by the easy to use software interface, removing the need for time consuming calculations performed by the user during analysis.
The fluorescent intensity is proportional to the concentrations of antibody captured on the beads.
Using fluorescence provides tremendous reliability and precision to give confidence in every result.
RapidQuant assays have been tested extensively with human and mouse antibodies of all IgG subtypes and in many types of hybridoma media and have performed well in all cases tested.
RapidQuant kits are extremely specific for IgG and are not hindered by the presence of FBS or IgM in the media.
The RapidQuant assay can be used to determine absolute concentrations of antibody present in cell culture medium or in purified preparations by comparison to a standard curve.
Results from this assay can also be combined with results from the Guava Express assay to determine relative antibody affinities.
The ViaCount assay has become a leading standard for viability and cell counting, says Guava.
Used in laboratories characterising antibodies the ViaCount assay provides a rapid and reliable assessment of the cell concentration and viability of clones for production.
Combining results from the RapidQuant and ViaCount assays delivers the benefit of simultaneous assessment of IgG production and cell health parameters.
